Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)-Reference-Cited by-同舟云学术

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Published:2022-12-31 Issue:1 Volume:198 Page:123-130
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Maschmann Raíra Mesquita,De Jesus Rafaela Gomes,Werutsky Gustavo,Rebelatto Taiane Francieli,Queiroz Geraldo,Simon Sergio Daniel,Bines José,Barrios Carlos Henrique Escosteguy,Rosa Daniela Dornelles^ORCID

Funder

Programa Nacional de Apoio à Atenção Oncológica

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06809-8.pdf

Reference29 articles.

1. Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE (2012) Breast cancer in Brazil: present status and future goals. Lancet Oncol 13(3):e95–e102. https://doi.org/10.1016/S1470-2045(11)70323-0

2. Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ (2019) Time to initial cancer treatment in the United States and association with survival over time: an observational study. PLoS ONE 14(3):e0213209. https://doi.org/10.1371/journal.pone.0213209.Erratum.In:PLoSOne.2019;14(4):e0215108

3. McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED (2012) Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30(36):4493–4500. https://doi.org/10.1200/JCO.2012.39.7695